Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer.

ABSTRACT:

Background

Conventional chemotherapy is based on the maximum tolerated dose (MTD) and requires treatment-free intervals to restore normal host cells. MTD chemotherapy may induce angiogenesis or immunosuppressive cell infiltration during treatment-free intervals. Low-dose metronomic (LDM) chemotherapy is defined as frequent administration at lower doses and causes less inflammatory change, whereas MTD chemotherapy induces an inflammatory change. Although several LDM regimens have been applied, LDM cisplatin (CDDP) has been rarely reported. This study addressed the efficacy of LDM CDDP on tumour endothelial cell phenotypic alteration compared to MTD CDDP.

Methods

Tumour growth and metastasis were assessed in bladder cancer-bearing mice treated with LDM or MTD gemcitabine (GEM)

SUBMITTER: Kikuchi H 

PROVIDER: S-EPMC10803316 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature